• Plus Therapeutics Inc PSTV.OQ reported a quarterly adjusted loss of 49 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -84 cents. The mean expectation of three analysts for the quarter was for a loss of 50 cents per share. Wall Street expected results to range from -58 cents to -43 cents per share.

• Revenue rose 7.5% to $1.41 million from a year ago; analysts expected $1.01 million.

• Plus Therapeutics Inc's reported EPS for the quarter was a loss of 49 cents​.

• The company reported a quarterly loss of $3.9 million.

• Plus Therapeutics Inc shares had risen by 27.8% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 25.7% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Plus Therapeutics Inc is $8.00

This summary was machine generated from LSEG data March 27 at 09:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)